SK281086B6 - Monoklonálne myšie antiidiotypové protilátky, spôsob ich prípravy, farmaceutický prostriedok a ich použitie - Google Patents

Monoklonálne myšie antiidiotypové protilátky, spôsob ich prípravy, farmaceutický prostriedok a ich použitie Download PDF

Info

Publication number: SK281086B6
Authority: SK; Slovakia
Prior art keywords: antibody; antibodies; serum; binding; mouse
Prior art date: 1992-05-22

Application number

SK1398-94A

Other languages

English (en)

Slovak (sk)

Other versions

SK139894A3 (en

Inventor

Helmut Eckert

Herbert Jaksche

Evelyne Janzek

Hans Loibner

Dieter Scholz

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-22

Filing date

1993-05-14

Publication date

2000-11-07

1992-05-22 Priority claimed from GB929210944A external-priority patent/GB9210944D0/en

1992-05-22 Priority claimed from GB929210930A external-priority patent/GB9210930D0/en

1992-05-22 Priority claimed from GB929210929A external-priority patent/GB9210929D0/en

1993-05-14 Application filed by Novartis Ag filed Critical Novartis Ag

1995-07-11 Publication of SK139894A3 publication Critical patent/SK139894A3/sk

2000-11-07 Publication of SK281086B6 publication Critical patent/SK281086B6/sk

Links

238000000034 method Methods 0.000 title claims abstract description 17
239000008194 pharmaceutical composition Substances 0.000 title claims 3
238000004519 manufacturing process Methods 0.000 title abstract description 5
230000003053 immunization Effects 0.000 claims abstract description 116
238000002649 immunization Methods 0.000 claims abstract description 116
206010028980 Neoplasm Diseases 0.000 claims abstract description 33
241001529936 Murinae Species 0.000 claims abstract description 28
230000001225 therapeutic effect Effects 0.000 claims abstract description 14
208000031886 HIV Infections Diseases 0.000 claims abstract description 7
201000011510 cancer Diseases 0.000 claims abstract description 7
206010041067 Small cell lung cancer Diseases 0.000 claims abstract description 5
208000000587 small cell lung carcinoma Diseases 0.000 claims abstract description 5
210000004027 cell Anatomy 0.000 claims description 154
241000282414 Homo sapiens Species 0.000 claims description 120
230000027455 binding Effects 0.000 claims description 111
241000699666 Mus <mouse, genus> Species 0.000 claims description 97
210000004408 hybridoma Anatomy 0.000 claims description 18
238000000746 purification Methods 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
239000012634 fragment Substances 0.000 claims description 10
230000003449 preventive effect Effects 0.000 claims description 10
239000002671 adjuvant Substances 0.000 claims description 8
241000699670 Mus sp. Species 0.000 claims description 7
230000005764 inhibitory process Effects 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 4
206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
201000000050 myeloid neoplasm Diseases 0.000 claims description 3
210000004989 spleen cell Anatomy 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 abstract description 2
210000002966 serum Anatomy 0.000 description 127
241000282693 Cercopithecidae Species 0.000 description 66
239000002953 phosphate buffered saline Substances 0.000 description 49
241000282560 Macaca mulatta Species 0.000 description 48
238000002965 ELISA Methods 0.000 description 42
239000002609 medium Substances 0.000 description 35
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
239000000872 buffer Substances 0.000 description 28
239000000427 antigen Substances 0.000 description 26
108091007433 antigens Proteins 0.000 description 26
102000036639 antigens Human genes 0.000 description 26
239000000243 solution Substances 0.000 description 24
210000004881 tumor cell Anatomy 0.000 description 24
239000006228 supernatant Substances 0.000 description 20
238000002474 experimental method Methods 0.000 description 19
230000028993 immune response Effects 0.000 description 18
239000011780 sodium chloride Substances 0.000 description 16
238000002835 absorbance Methods 0.000 description 15
241000283973 Oryctolagus cuniculus Species 0.000 description 14
238000010790 dilution Methods 0.000 description 14
239000012895 dilution Substances 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
239000011651 chromium Substances 0.000 description 12
238000005259 measurement Methods 0.000 description 12
108060003951 Immunoglobulin Proteins 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
102000018358 immunoglobulin Human genes 0.000 description 11
206010006187 Breast cancer Diseases 0.000 description 10
208000026310 Breast neoplasm Diseases 0.000 description 10
229920002684 Sepharose Polymers 0.000 description 10
241000700605 Viruses Species 0.000 description 10
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
150000001720 carbohydrates Chemical class 0.000 description 10
201000010099 disease Diseases 0.000 description 10
102000013415 peroxidase activity proteins Human genes 0.000 description 10
108040007629 peroxidase activity proteins Proteins 0.000 description 10
239000011534 wash buffer Substances 0.000 description 10
238000003556 assay Methods 0.000 description 9
229910002091 carbon monoxide Inorganic materials 0.000 description 9
230000021615 conjugation Effects 0.000 description 9
238000001514 detection method Methods 0.000 description 9
230000004044 response Effects 0.000 description 9
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
239000011248 coating agent Substances 0.000 description 8
238000000576 coating method Methods 0.000 description 8
238000011534 incubation Methods 0.000 description 8
239000012528 membrane Substances 0.000 description 8
238000002255 vaccination Methods 0.000 description 8
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 7
238000011088 calibration curve Methods 0.000 description 7
230000001413 cellular effect Effects 0.000 description 7
239000012149 elution buffer Substances 0.000 description 7
238000010166 immunofluorescence Methods 0.000 description 7
201000001441 melanoma Diseases 0.000 description 7
238000010186 staining Methods 0.000 description 7
239000000758 substrate Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
230000005809 anti-tumor immunity Effects 0.000 description 6
239000012148 binding buffer Substances 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
239000012636 effector Substances 0.000 description 6
230000002163 immunogen Effects 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
239000011734 sodium Substances 0.000 description 6
230000002269 spontaneous effect Effects 0.000 description 6
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
230000008033 biological extinction Effects 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
229940072221 immunoglobulins Drugs 0.000 description 5
238000001155 isoelectric focusing Methods 0.000 description 5
239000003446 ligand Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000013049 sediment Substances 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 4
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000005889 cellular cytotoxicity Effects 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
239000012737 fresh medium Substances 0.000 description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000013642 negative control Substances 0.000 description 4
229940056360 penicillin g Drugs 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
229960002385 streptomycin sulfate Drugs 0.000 description 4
229960005486 vaccine Drugs 0.000 description 4
GHCVXTFBVDVFGE-UHFFFAOYSA-N 4-amino-6-chloro-1,3,5-triazin-2-ol Chemical compound NC1=NC(O)=NC(Cl)=N1 GHCVXTFBVDVFGE-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
108010032595 Antibody Binding Sites Proteins 0.000 description 3
108010047041 Complementarity Determining Regions Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
206010061968 Gastric neoplasm Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
208000007521 HIV Seropositivity Diseases 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000003149 assay kit Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000006957 competitive inhibition Effects 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000003795 desorption Methods 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
229940031098 ethanolamine Drugs 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
108060003552 hemocyanin Proteins 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
230000036039 immunity Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
210000005265 lung cell Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
239000002245 particle Substances 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000002594 sorbent Substances 0.000 description 3
241000894007 species Species 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
208000007660 Residual Neoplasm Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000003302 anti-idiotype Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000007969 cellular immunity Effects 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000012482 interaction analysis Methods 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
208000037841 lung tumor Diseases 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
230000010807 negative regulation of binding Effects 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000002482 oligosaccharides Chemical class 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
238000004513 sizing Methods 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
239000007858 starting material Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000700112 Chinchilla Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
101710141347 Major envelope glycoprotein Proteins 0.000 description 1
241000542855 Megathura crenulata Species 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
-1 SW948 Chemical compound 0.000 description 1
208000028495 Schilbach-Rott syndrome Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
229940073579 ethanolamine hydrochloride Drugs 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229940043504 normal human immunoglobulins Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000002516 postimmunization Effects 0.000 description 1
238000012910 preclinical development Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
FFISLTWEISOMFC-UHFFFAOYSA-N pyridin-2-yl propanedithioate Chemical compound CCC(=S)SC1=CC=CC=N1 FFISLTWEISOMFC-UHFFFAOYSA-N 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000000954 titration curve Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Oncology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Wood Science & Technology (AREA)

SK1398-94A 1992-05-22 1993-05-14 Monoklonálne myšie antiidiotypové protilátky, spôsob ich prípravy, farmaceutický prostriedok a ich použitie SK281086B6 (sk)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB929210944A GB9210944D0 (en)	1992-05-22	1992-05-22	Monoclonal antibodies and their use
GB929210930A GB9210930D0 (en)	1992-05-22	1992-05-22	Monoclonal antibodies and their use
GB929210929A GB9210929D0 (en)	1992-05-22	1992-05-22	Monoclonal antibodies and their use
PCT/EP1993/001215 WO1993024647A1 (en)	1992-05-22	1993-05-14	Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses

Publications (2)

Publication Number	Publication Date
SK139894A3 SK139894A3 (en)	1995-07-11
SK281086B6 true SK281086B6 (sk)	2000-11-07

Family

ID=27266199

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1398-94A SK281086B6 (sk)	1992-05-22	1993-05-14	Monoklonálne myšie antiidiotypové protilátky, spôsob ich prípravy, farmaceutický prostriedok a ich použitie

Country Status (20)

Country	Link
EP (1)	EP0644947B1 (fi)
JP (3)	JPH07507207A (fi)
KR (1)	KR100279317B1 (fi)
AT (1)	ATE179214T1 (fi)
AU (1)	AU678160B2 (fi)
CA (1)	CA2134751C (fi)
CZ (1)	CZ286547B6 (fi)
DE (1)	DE69324584T2 (fi)
DK (1)	DK0644947T3 (fi)
ES (1)	ES2133395T3 (fi)
FI (1)	FI111518B (fi)
GR (1)	GR3030701T3 (fi)
HU (1)	HU219055B (fi)
NO (1)	NO316120B1 (fi)
NZ (1)	NZ252161A (fi)
PL (1)	PL175651B1 (fi)
RU (1)	RU2208642C2 (fi)
SG (1)	SG50721A1 (fi)
SK (1)	SK281086B6 (fi)
WO (1)	WO1993024647A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT500650B1 (de) *	2003-04-17	2009-11-15	Altropus Gmbh	Immunogener rekombinanter antikörper
CN1867587A (zh) *	2003-08-14	2006-11-22	惠氏公司	抗Lewis Y抗独特型抗体及其用途
AT504231A1 (de)	2006-10-03	2008-04-15	Hans Dr Loibner	Prädiktive parameter
JP5985481B2 (ja) *	2010-09-01	2016-09-06	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	抗イディオタイプ抗体の迅速な産生
RU2735653C2 (ru) *	2016-08-23	2020-11-05	Тран-Сцелл Биологицс Привате Лимитед	Платформа с клетками-предшественниками человека для поиска активных веществ лекарственных препаратов

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH03505668A (ja) *	1988-07-06	1991-12-12	ヴェリガン・インコーポレーテッド	Ｇｐ４８に対する特異抗体
DE4006308A1 (de) *	1990-02-28	1991-08-29	Sandoz Ag	Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
DE4025499A1 (de) *	1990-08-11	1992-02-13	Sandoz Ag	Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen
ATE188708T1 (de) *	1991-08-21	2000-01-15	Novartis Ag	Antikörperderivate

1993
- 1993-05-14 ES ES93909997T patent/ES2133395T3/es not_active Expired - Lifetime
- 1993-05-14 CZ CZ19942851A patent/CZ286547B6/cs not_active IP Right Cessation
- 1993-05-14 NZ NZ252161A patent/NZ252161A/en unknown
- 1993-05-14 PL PL93306001A patent/PL175651B1/pl not_active IP Right Cessation
- 1993-05-14 KR KR1019940704163A patent/KR100279317B1/ko not_active IP Right Cessation
- 1993-05-14 RU RU94046321/13A patent/RU2208642C2/ru not_active IP Right Cessation
- 1993-05-14 DK DK93909997T patent/DK0644947T3/da active
- 1993-05-14 SG SG1996009665A patent/SG50721A1/en unknown
- 1993-05-14 AU AU40688/93A patent/AU678160B2/en not_active Ceased
- 1993-05-14 AT AT93909997T patent/ATE179214T1/de not_active IP Right Cessation
- 1993-05-14 HU HU9403337A patent/HU219055B/hu not_active IP Right Cessation
- 1993-05-14 SK SK1398-94A patent/SK281086B6/sk unknown
- 1993-05-14 EP EP93909997A patent/EP0644947B1/en not_active Expired - Lifetime
- 1993-05-14 WO PCT/EP1993/001215 patent/WO1993024647A1/en active IP Right Grant
- 1993-05-14 DE DE69324584T patent/DE69324584T2/de not_active Expired - Fee Related
- 1993-05-14 CA CA002134751A patent/CA2134751C/en not_active Expired - Fee Related
- 1993-05-14 JP JP6500128A patent/JPH07507207A/ja active Pending
1994
- 1994-11-21 NO NO19944443A patent/NO316120B1/no unknown
- 1994-11-22 FI FI945485A patent/FI111518B/fi not_active IP Right Cessation
1998
- 1998-09-03 JP JP10249573A patent/JPH11178594A/ja active Pending
1999
- 1999-07-07 GR GR990401784T patent/GR3030701T3/el unknown
2005
- 2005-11-30 JP JP2005346456A patent/JP2006143738A/ja active Pending

Also Published As

Publication number	Publication date
FI945485A0 (fi)	1994-11-22
CZ285194A3 (en)	1995-05-17
HUT71311A (en)	1995-11-28
AU678160B2 (en)	1997-05-22
PL175651B1 (pl)	1999-01-29
CZ286547B6 (cs)	2000-05-17
NZ252161A (en)	1996-10-28
AU4068893A (en)	1993-12-30
GR3030701T3 (en)	1999-11-30
SG50721A1 (en)	2000-11-21
SK139894A3 (en)	1995-07-11
EP0644947B1 (en)	1999-04-21
HU219055B (hu)	2001-02-28
NO316120B1 (no)	2003-12-15
ES2133395T3 (es)	1999-09-16
FI945485A (fi)	1994-11-22
FI111518B (fi)	2003-08-15
KR100279317B1 (ko)	2001-01-15
DE69324584T2 (de)	1999-09-23
NO944443D0 (no)	1994-11-21
ATE179214T1 (de)	1999-05-15
JP2006143738A (ja)	2006-06-08
JPH11178594A (ja)	1999-07-06
EP0644947A1 (en)	1995-03-29
DE69324584D1 (de)	1999-05-27
RU94046321A (ru)	1997-01-27
KR950701685A (ko)	1995-04-28
RU2208642C2 (ru)	2003-07-20
NO944443L (no)	1995-01-20
DK0644947T3 (da)	1999-11-01
JPH07507207A (ja)	1995-08-10
CA2134751A1 (en)	1993-12-09
WO1993024647A1 (en)	1993-12-09
CA2134751C (en)	2003-12-16

Publication	Publication Date	Title
Uytdehaag et al.	1985	Induction of neutralizing antibody in mice against poliovirus type II with monoclonal anti-idiotypic antibody.
EP1241264A1 (en)	2002-09-18	Monoclonal antibodies to colon cancer antigen
US5653977A (en)	1997-08-05	Anti-idiotypic antibody that mimics the GD2 antigen
KR920008744B1 (ko)	1992-10-09	Hiv 감염의 치료 및 진단용 모노클로날항체 및 펩티드
KR19990087425A (ko)	1999-12-27	알레르기에 대한 백신 접종 및 치료를 위한 펩티드 임뮤노겐
US20110212106A1 (en)	2011-09-01	Hiv-1 neutralizing antibodies and uses thereof
NZ505174A (en)	2002-03-01	Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer
AU2003214044B8 (en)	2008-11-13	Anti-idiotypic antibody inducing HIV-1 neutralizing antibodies
FI111518B (fi)	2003-08-15	Menetelmä monoklonaalisten vasta-aineiden ja vasta-ainetta sisältävän farmaseuttisen koostumuksen valmistamiseksi
CA1341391C (en)	2002-10-01	Protective peptides derived from human immunodeficiency virus-1 gp160
US20020146410A1 (en)	2002-10-10	Monoclonal antibodies and their use
JPH04501061A (ja)	1992-02-27	抗イディオタイプ抗体による抗腫瘍応答の誘導
EP0370090B1 (en)	1996-07-10	Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens
Powell Jr et al.	1988	Activation of a functional idiotype network response by monoclonal antibody specific for a virus (M-MuLV)-induced tumor antigen.
US20060177454A1 (en)	2006-08-10	Method of promoting an immune response with a bispecific antibody
EP0344211A1 (en)	1989-12-06	Monoclonal antibodies in vaccine formulations
JPH06506947A (ja)	1994-08-04	抗ウィルスハイブリッド抗体
Kearney et al.	0	Thomas J. Powell, Jr., Richard Spann, Meenal Vakil
NZ503032A (en)	2001-11-30	Use of a binding agent to reconforming multi-epitopic antigens to initiate an immune response